Technology
Health
Pharmaceutical

Galmed Pharmaceuticals

$6.86
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.07 (-1.01%) Today
-$0.02 (-0.29%) After Hours

Why Robinhood?

You can buy or sell GLMD and other stocks, options, ETFs, and crypto commission-free!

About

Galmed Pharmaceuticals Ltd. Ordinary Shares, also called Galmed Pharmaceuticals, is a clinical-stage biopharmaceutical company. Read More It focuses on the development of the liver targeted stearoyl-coenzyme A desaturase-1 modulator Aramchol, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. The Aramchol is a synthetic conjugate of cholic acid, or a type of bile acid, and arachidic acid, or a type of saturated fatty acid, both of which, in their non-synthetic forms, are naturally occurring. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Employees
21
Headquarters
Tel Aviv, Tel Aviv
Founded
2000
Market Cap
145.26M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
306.14K
High Today
$6.96
Low Today
$6.81
Open Price
$6.92
Volume
15.11K
52 Week High
$27.06
52 Week Low
$5.58

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
Therapy
2014 IPO
Asia (Non-China)

News

Seeking AlphaMay 7

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q1 2019 Results - Earnings Call Transcript

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Q1 2019 Earnings Conference Call May 7, 2019 8:30 AM ET Company Participants Allen Baharaff - President & Chief Executive Officer Liat Hayardeny - Chief Scientific Officer Tali Gorfine - Chief Medical Officer Yohai Stenzler - Chief Financial Officer Conference Call Participants Steve Seedhouse - Raymond James Mayank Mamtani - B. Riley Thomas Yip - H.C Operator Good day, and welcome to the Galmed Conference Call to discuss Financial Results for the First Q...

75
NasdaqMay 7

Galmed Pharmaceuticals (GLMD) Reports Q1 Loss, Misses Revenue Estimates

Galmed Pharmaceuticals (GLMD) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.17 per share a year ago.

13
Yahoo FinanceMay 7

Galmed Pharmaceuticals: 1Q Earnings Snapshot

TEL AVIV, Israel (AP) _ Galmed Pharmaceuticals Ltd. (GLMD) on Tuesday reported a loss of $3.5 million in its first quarter. On a per-share basis, the Tel Aviv, Israel-based company said it had a loss of 17 cents. The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 19 cents per share. Galmed Pharmaceuticals shares have increased 10% since the beginning of the year. The stock has increased 27% in the last 12 months. _____ ...

11

Earnings

-$0.27
-$0.20
-$0.12
-$0.05
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.20 per share
Actual
-$0.17 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.